MXPA02011043A - Nuevos derivados antagonistas del receptor de la vitronectina. - Google Patents

Nuevos derivados antagonistas del receptor de la vitronectina.

Info

Publication number
MXPA02011043A
MXPA02011043A MXPA02011043A MXPA02011043A MXPA02011043A MX PA02011043 A MXPA02011043 A MX PA02011043A MX PA02011043 A MXPA02011043 A MX PA02011043A MX PA02011043 A MXPA02011043 A MX PA02011043A MX PA02011043 A MXPA02011043 A MX PA02011043A
Authority
MX
Mexico
Prior art keywords
vitronectin receptor
receptor antagonists
novel
formula
novel vitronectin
Prior art date
Application number
MXPA02011043A
Other languages
English (en)
Spanish (es)
Inventor
Jean-Francois Gourvest
Original Assignee
Aventis Pharma Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Aventis Pharma Sa filed Critical Aventis Pharma Sa
Publication of MXPA02011043A publication Critical patent/MXPA02011043A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Oncology (AREA)
  • Pain & Pain Management (AREA)
  • Ophthalmology & Optometry (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
MXPA02011043A 2000-05-09 2001-05-04 Nuevos derivados antagonistas del receptor de la vitronectina. MXPA02011043A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR0005859A FR2808798A1 (fr) 2000-05-09 2000-05-09 Nouveaux derives antagonistes du recepteur de la vitronectine
PCT/FR2001/001357 WO2001085729A1 (fr) 2000-05-09 2001-05-04 Nouveaux derives antagonistes du recepteur de la vitronectine

Publications (1)

Publication Number Publication Date
MXPA02011043A true MXPA02011043A (es) 2003-03-10

Family

ID=8850000

Family Applications (1)

Application Number Title Priority Date Filing Date
MXPA02011043A MXPA02011043A (es) 2000-05-09 2001-05-04 Nuevos derivados antagonistas del receptor de la vitronectina.

Country Status (12)

Country Link
US (1) US6838453B2 (enExample)
EP (1) EP1282621B1 (enExample)
JP (1) JP5143989B2 (enExample)
AT (1) ATE304012T1 (enExample)
AU (1) AU2001258489A1 (enExample)
CA (1) CA2408293A1 (enExample)
DE (1) DE60113248T2 (enExample)
ES (1) ES2249431T3 (enExample)
FR (1) FR2808798A1 (enExample)
IL (1) IL152613A0 (enExample)
MX (1) MXPA02011043A (enExample)
WO (1) WO2001085729A1 (enExample)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP3332679B2 (ja) 1995-08-08 2002-10-07 昭和電工株式会社 押継ぎ押出用ダイス
PL371841A1 (pl) * 2004-12-20 2006-06-26 ADAMED Sp.z o.o. Nowe związki pochodne kwasu 3-fenylopropionowego
PL372332A1 (pl) 2005-01-19 2006-07-24 ADAMED Sp.z o.o. Nowe związki, pochodne kwasu 3-fenylopropionowego
PL372356A1 (pl) * 2005-01-20 2006-07-24 ADAMED Sp.z o.o. Nowe związki, pochodne kwasu 3-fenylopropionowego
EP3481814B1 (en) 2016-07-05 2022-04-27 The Rockefeller University Tetrahydronaphthyridinepentanamide integrin antagonists

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5296486A (en) * 1991-09-24 1994-03-22 Boehringer Ingelheim Pharmaceuticals, Inc. Leukotriene biosynthesis inhibitors
GB9604242D0 (en) * 1996-02-28 1996-05-01 Glaxo Wellcome Inc Chemical compounds
DE19629816A1 (de) * 1996-07-24 1998-01-29 Hoechst Ag Neue Cycloalkyl-Derivate als Inhibitoren der Knochenresorption und Vitronectinrezeptor-Antagonisten
DE19629817A1 (de) * 1996-07-24 1998-01-29 Hoechst Ag Neue Imino-Derivate als Inhibitoren der Knochenresorption und Vitronectinrezeptor-Antagonisten
EP0933367A1 (en) * 1997-12-19 1999-08-04 Hoechst Marion Roussel Deutschland GmbH Novel acylguanidine derivates as inhibitors of bone resorption and as vitronectin receptor antagonists
AP1269A (en) * 1998-01-23 2004-04-03 Aventis Pharma Deutschland Gmbh Novel salfonamide derivatives as inhibitors of bone resorption and as inhibitors of cell adhesion.
AR015241A1 (es) * 1998-03-10 2001-04-18 Smithkline Beecham Corp Antagonistas del receptor de vitronectina composicion farmaceutica que los contiene, procedimiento para su preparacion y su empleo para la fabricacion deun medicamento.
ATE253061T1 (de) * 1998-06-29 2003-11-15 Iaf Biochem Int Zur behandlung von krebs nützliche thiophen- und furan-2,5-dicarboxamide
HK1040076A1 (zh) * 1998-09-21 2002-05-24 希雷生物化学有限公司 作为整联蛋白抑制剂的喹嗪酮
GB9821061D0 (en) * 1998-09-28 1998-11-18 Celltech Therapeutics Ltd Chemical compounds

Also Published As

Publication number Publication date
EP1282621A1 (fr) 2003-02-12
JP2003532732A (ja) 2003-11-05
ES2249431T3 (es) 2006-04-01
ATE304012T1 (de) 2005-09-15
DE60113248D1 (de) 2005-10-13
FR2808798A1 (fr) 2001-11-16
CA2408293A1 (fr) 2001-11-15
JP5143989B2 (ja) 2013-02-13
US20040225111A1 (en) 2004-11-11
US6838453B2 (en) 2005-01-04
IL152613A0 (en) 2003-06-24
AU2001258489A1 (en) 2001-11-20
DE60113248T2 (de) 2006-06-29
WO2001085729A1 (fr) 2001-11-15
EP1282621B1 (fr) 2005-09-07

Similar Documents

Publication Publication Date Title
MY122392A (en) Adamantane derivatives of use of p2x7 receptor antagonists, a process for their preparation, pharmaceutical compositions containing them and a process for preparing the pharmaceutical compositions
ZA200700765B (en) Nebivolol and its pharmaceutically acceptable salts, process for preparation and pharmaceutical compositions of nebivolol
ATE316083T1 (de) Adamantanderivate
PL361361A1 (en) Substituted 1-aminoalkyl-lactams and their use as muscarinic receptor antagonists
SE9904505D0 (sv) Novel compounds
IL150085A0 (en) New-p2x7 receptor antagonists for use in the treatment of inflammatory, immune or cardiovascular diseases
MY138086A (en) Novel urea derivative as vanilloid receptor-1 antagonist
BR0213562A (pt) Benzimidazóis e análogos e seu uso como inibidores de cinases de proteìna
ES2158814B1 (es) Derivados de pirrolidina antagonistas del receptor ccr-3
MXPA05012678A (es) Forma cristalina del agonista del receptor adrenergico beta2.
SG147466A1 (en) Thrombin receptor antagonists
MX2009006018A (es) Derivados de quinuclidinol como antagonistas de receptores muscarinicos.
MY138734A (en) Casr antagonist
MXPA04002338A (es) Derivados de carbazol y su uso como antagonistas receptores del npy5.
MY140835A (en) Substituted 1-aminoalkyl-lactams and their use as muscarinic receptor antagonists
MXPA04001968A (es) Agentes antidiabeticos.
MY133445A (en) 2-arylethyl-(piperidin-4-ylmethyl)amine derivetives
DE60217843D1 (de) Ein dioxinoä2,3-güchinolin-9-carbonsäure derivat als nk3 rezeptor antagonist
PL372457A1 (en) New pharmaceutical compositions containing flibanserin polymorph a
MXPA04005076A (es) Derivados de 4-piperidinil alquilamina como antagonistas del receptor muscarinico.
MXPA04005313A (es) Derivados de aminotetralin como antagonistas del receptor muscarinico.
WO2001010860A3 (en) Quinazolinone and azaquinazolinone derivatives
IL152613A0 (en) Novel vitronectin receptor antagonists
MXPA05011841A (es) Metil-indoles y metil-pirrolopiridinas como agonistas adrenergicos de alfa-1.
MXPA05005340A (es) Nuevos derivados antagonistas del receptor de la vitronectina, sus procedimientos de preparacion, su aplicacion como medicamentos y los compuestos farmaceuticos que los contienen.